Search
Hydroxyprogesterone
go.drugbank.com/drugs/DB14570InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPrednisolone hemisuccinate
go.drugbank.com/drugs/DB14633InvestigationalCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersGDC-0425
go.drugbank.com/drugs/DB14791InvestigationalGDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory
Uproleselan
go.drugbank.com/drugs/DB14829InvestigationalUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Mipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Categories: P-glycoprotein substratesDexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalDexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to...
Categories: Compounds used in a research, industrial, or household setting2-Hydroxylpropyl-beta-cyclodextrin
go.drugbank.com/drugs/DB15146InvestigationalAdrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).
Categories: Compounds used in a research, industrial, or household settingBrensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InducersNevanimibe
go.drugbank.com/drugs/DB16254InvestigationalNevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).
Dexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnDexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. … For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates